Prelude Therapeutics Incorporated (PRLD) is a Biotechnology company in the Healthcare sector, currently trading at $4.40. It has a SharesGrow Score of 55/100, indicating a above average investment profile with 4 out of 7 criteria passed.
Analyst consensus target is PRLD = $6 (+42% upside).
Valuation: PRLD trades at a trailing Price-to-Earnings (P/E) of -2.4 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.04.
Financials: revenue is $12M, +73.4%/yr average growth. Net income is $99M (loss), growing at +1.3%/yr. Net profit margin is -819.6% (negative). Gross margin is 85.9% (-14.1 pp trend).
Balance sheet: total debt is $18M against $69M equity (Debt-to-Equity (D/E) ratio 0.26, conservative). Current ratio is 1.99 (strong liquidity). Debt-to-assets is 12.6%. Total assets: $141M.
Analyst outlook: 5 / 8 analysts rate PRLD as buy (63%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 96/100 (Pass), Growth 73/100 (Pass), Past 0/100 (Fail), Health 100/100 (Pass), Moat 35/100 (Fail), Future 73/100 (Pass), Income 10/100 (Fail).
